Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein

Gini F. Fleming, Jacqueline M. Amato, Michael Agresti, Ahmad Safa

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

We evaluated the multidrug resistance (MDR)-modulating effects of progesterone (PRG) and an orally active, structurally related compound, megestrol acetate (MA), in several MDR human cell lines. At 100 μm, both steroids inhibited the binding of a Vinca alkaloid photoaffinity analog to P-glycoprotein (P-gp) in MDR human neuroblastic SH-SY5Y/VCR cells [which show >1500-fold resistance to vincristine (VCR) in the tetrazolium dye (MTT) assay]. However, 100 μm MA markedly enhanced the binding of [3H]-azidopine to P-gp in both SH-SY5Y/VCR cells and the MDR human epidermoid KB-GSV2 cell line (which displays 250-fold resistance to VCR in the MTT assay). PRG had little effect on the binding of [3H]-azidopine to P-gp. MA at low doses was more effective than PRG in sensitizing cells to VCR and enhancing their accumulation of [3H]-VCR. The highly resistant SH-SY5Y/VCR subline exhibited significant collateral sensitivity to both steroids. These data suggest that MA may be a clinically useful modulator of MDR.

Original languageEnglish (US)
Pages (from-to)445-449
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume29
Issue number6
DOIs
StatePublished - Nov 1992
Externally publishedYes

Fingerprint

Megestrol Acetate
Multiple Drug Resistance
P-Glycoprotein
Vincristine
Progesterone
Assays
Steroids
Cells
Vinca Alkaloids
KB Cells
Cell Line
Modulators
Coloring Agents

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein. / Fleming, Gini F.; Amato, Jacqueline M.; Agresti, Michael; Safa, Ahmad.

In: Cancer Chemotherapy and Pharmacology, Vol. 29, No. 6, 11.1992, p. 445-449.

Research output: Contribution to journalArticle

Fleming, Gini F. ; Amato, Jacqueline M. ; Agresti, Michael ; Safa, Ahmad. / Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein. In: Cancer Chemotherapy and Pharmacology. 1992 ; Vol. 29, No. 6. pp. 445-449.
@article{060f854c759348b1aa49c5d44d00a7d2,
title = "Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein",
abstract = "We evaluated the multidrug resistance (MDR)-modulating effects of progesterone (PRG) and an orally active, structurally related compound, megestrol acetate (MA), in several MDR human cell lines. At 100 μm, both steroids inhibited the binding of a Vinca alkaloid photoaffinity analog to P-glycoprotein (P-gp) in MDR human neuroblastic SH-SY5Y/VCR cells [which show >1500-fold resistance to vincristine (VCR) in the tetrazolium dye (MTT) assay]. However, 100 μm MA markedly enhanced the binding of [3H]-azidopine to P-gp in both SH-SY5Y/VCR cells and the MDR human epidermoid KB-GSV2 cell line (which displays 250-fold resistance to VCR in the MTT assay). PRG had little effect on the binding of [3H]-azidopine to P-gp. MA at low doses was more effective than PRG in sensitizing cells to VCR and enhancing their accumulation of [3H]-VCR. The highly resistant SH-SY5Y/VCR subline exhibited significant collateral sensitivity to both steroids. These data suggest that MA may be a clinically useful modulator of MDR.",
author = "Fleming, {Gini F.} and Amato, {Jacqueline M.} and Michael Agresti and Ahmad Safa",
year = "1992",
month = "11",
doi = "10.1007/BF00684845",
language = "English (US)",
volume = "29",
pages = "445--449",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein

AU - Fleming, Gini F.

AU - Amato, Jacqueline M.

AU - Agresti, Michael

AU - Safa, Ahmad

PY - 1992/11

Y1 - 1992/11

N2 - We evaluated the multidrug resistance (MDR)-modulating effects of progesterone (PRG) and an orally active, structurally related compound, megestrol acetate (MA), in several MDR human cell lines. At 100 μm, both steroids inhibited the binding of a Vinca alkaloid photoaffinity analog to P-glycoprotein (P-gp) in MDR human neuroblastic SH-SY5Y/VCR cells [which show >1500-fold resistance to vincristine (VCR) in the tetrazolium dye (MTT) assay]. However, 100 μm MA markedly enhanced the binding of [3H]-azidopine to P-gp in both SH-SY5Y/VCR cells and the MDR human epidermoid KB-GSV2 cell line (which displays 250-fold resistance to VCR in the MTT assay). PRG had little effect on the binding of [3H]-azidopine to P-gp. MA at low doses was more effective than PRG in sensitizing cells to VCR and enhancing their accumulation of [3H]-VCR. The highly resistant SH-SY5Y/VCR subline exhibited significant collateral sensitivity to both steroids. These data suggest that MA may be a clinically useful modulator of MDR.

AB - We evaluated the multidrug resistance (MDR)-modulating effects of progesterone (PRG) and an orally active, structurally related compound, megestrol acetate (MA), in several MDR human cell lines. At 100 μm, both steroids inhibited the binding of a Vinca alkaloid photoaffinity analog to P-glycoprotein (P-gp) in MDR human neuroblastic SH-SY5Y/VCR cells [which show >1500-fold resistance to vincristine (VCR) in the tetrazolium dye (MTT) assay]. However, 100 μm MA markedly enhanced the binding of [3H]-azidopine to P-gp in both SH-SY5Y/VCR cells and the MDR human epidermoid KB-GSV2 cell line (which displays 250-fold resistance to VCR in the MTT assay). PRG had little effect on the binding of [3H]-azidopine to P-gp. MA at low doses was more effective than PRG in sensitizing cells to VCR and enhancing their accumulation of [3H]-VCR. The highly resistant SH-SY5Y/VCR subline exhibited significant collateral sensitivity to both steroids. These data suggest that MA may be a clinically useful modulator of MDR.

UR - http://www.scopus.com/inward/record.url?scp=0026572562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026572562&partnerID=8YFLogxK

U2 - 10.1007/BF00684845

DO - 10.1007/BF00684845

M3 - Article

C2 - 1348973

AN - SCOPUS:0026572562

VL - 29

SP - 445

EP - 449

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -